Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ImmunoGen Inc. IMGN

Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent. The technology is used in Kadcyla (ado-trastuzumab emtansine)--a registered trademark of Genentech, a member of the Roche Group--to kill solid tumors. Companies such as Amgen, Genentech/Roche, Lilly, Novartis, Sanofi, and Takeda have...


Recent & Breaking News (NDAQ:IMGN)

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 6 days ago

ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results

Business Wire 9 days ago

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

Business Wire July 14, 2022

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 1, 2022

ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

Business Wire June 13, 2022

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 1, 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Business Wire May 26, 2022

ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

Business Wire May 25, 2022

ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

Business Wire May 23, 2022

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

Business Wire May 10, 2022

ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results

Business Wire May 6, 2022

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire May 2, 2022

ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results

Business Wire April 21, 2022

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 1, 2022

ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference

Business Wire March 31, 2022

ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

Business Wire March 29, 2022

ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting

Business Wire March 19, 2022

ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting

Business Wire March 10, 2022

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 1, 2022

ImmunoGen Reports Recent Progress and 2021 Financial Results

Business Wire February 25, 2022